Childhood medulloblastoma: The paradigm shift in molecular stratification and treatment profile

Journal of Child Neurology

Volumn 27, Issue 10, 2012, Pages 1302-1307

  Sadighi, Zsila ^a   Vats, Tribhawan ^a   Khatua, Soumen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

medulloblastoma; molecular subgroup classification; pediatric

Indexed keywords

MEMBRANE PROTEIN; SHH PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB; WNT PROTEIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GENETICS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CEREBELLUM; CHILDHOOD CANCER; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MEDICAL LITERATURE; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

CEREBELLAR NEOPLASMS; CHILD, PRESCHOOL; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; PEDIATRICS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84866873464     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073812449690     Document Type: Review

References (26)

1. Louis DN WHO Classification of Tumors of the Central Nervous System. 4 th ed. Lyon, France: International Agency for Research on Cancer; 2007. Lyon, France: International Agency for Research on Cancer ; 2007:
2. Ellison DW. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol. 2010 ; 120 (3). 305-316
3. Tamayo P, Cho Y, Tsherniak A, et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 ; 29 (11). 1415-1423
4. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE. 2008 ; 3 (8). e3088
5. Rutowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol. 2010 ; 28 ((33)). 4961-4968
6. Packer RJ. Risk stratification of medulloblastoma: a paradigm for future childhood brain tumor management strategies. Curr Neurol Neurosci Rep. 2011 ; 11 ((2)). 124-126
7. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010 ; 468 (7327). 1095-1099
8. Bae G, Domene S, Roessler E, et al. Mutations in CDON, encoding a hedgehog receptor, result in holoprosencephaly and defective interactions with other hedgehog receptors. Am J Hum Genet. 2011 ; 89 (2). 231-240
9. Srivastava VK, Nalbantoglu J. The cellular and developmental biology of medulloblastoma current perspectives on experimental therapeutics. Cancer Biol Ther. 2010 ; 9 (11). 843-852
10. Baryawno N, Sveinbjornsson B, Kogner PV, Johnson JI. Medulloblastoma: a disease with disorganized developmental signaling cascades. Cell Cycle. 2010 ; 9 (13). 2548-2554
11. Saran A. Medulloblastoma: role of developmental pathways, DNA repair signaling and other players. Curr Mol Med. 2009 ; 9 ((9)). 1046-1057
12. Behesti H, Marino S. Cerebellar granule cells: insights into proliferation, differentiation, and role in medulloblastoma pathogenesis. Int J Biochem Cell Biol. 2009 ; 41 (3). 435-445
13. Onvani S, Etame AB, Smith CA, Rutka JT. Genetics of medulloblastoma: clues for novel therapies. Expert Rev Neurother. 2010 ; 10 (5). 811-823
14. Slade I, Murray A, Hanks S, et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer. 2011 ; 10 ((2)). 337-342
15. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011 ; 29 ((11)). 1408-1414
16. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 ; 24 (12). 1924-1931
17. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2010 ; 29 (11). 1424-1430
18. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic and molecular variables. J Clin Oncol. 2011 ; 29 (11). 1400-1407
19. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011 ; 121 ((3)). 381-396
20. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 ; 123 (4). 465-472
21. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009 ; 361 (12). 1173-1178
22. Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential therapeutics. Cancer Res. 2005 ; 65 (12). 4975-4978
23. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res. 2011 ; 71 (15). 5057-5061
24. Yauch RL, Dijkgraff GJ, Akicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science. 2009 ; 326 (5952). 572-574
25. Baryawno N, Sveinbjornsson B, Eksborg S, et al. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/B-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 2010 ; 70 (1). 266-276
26. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3 K pathway in medulloblastoma. Sci Transl Med. 2010 ; 2 (51). 51-70